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Summary
Objective: The investigation aimed at determining the effectiveness of pulsed electromagnetic ﬁelds (PEMF) in the treatment of osteoarthritis
(OA) of the knee by conducting a randomized, double-blind, placebo-controlled clinical trial.
Design: The trial consisted of 2 h daily treatment 5 days per week for 6 weeks in 83 patients with knee OA. Patient evaluations were done at
baseline and after 2 and 6 weeks of treatment. A follow-up evaluation was done 6 weeks after treatment. Activities of daily living (ADL), pain
and stiffness were evaluated using the Western Ontario and McMaster Universities (WOMAC) questionnaire.
Results: Within group analysis revealed a signiﬁcant improvement in ADL, stiffness and pain in the PEMF-treated group at all evaluations. In
the control group there was no effect on ADL after 2 weeks and a weak signiﬁcance was seen after 6 and 12 weeks. Signiﬁcant effects were
seen on pain at all evaluations and on stiffness after 6 and 12 weeks. Between group analysis did not reveal signiﬁcant improvements over
time. Analysis of ADL score for the PEMF-treated group revealed a signiﬁcant correlation between less improvement and increasing age.
Analysis of patients!65 years using between group analysis revealed a signiﬁcant improvement for stiffness on treated knee after 2 weeks,
but this effect was not observed for ADL and pain.
Conclusions: Applying between group analysis we were unable to demonstrate a beneﬁcial symptomatic effect of PEMF in the treatment of
knee OA in all patients. However, in patients !65 years of age there is signiﬁcant and beneﬁcial effect of treatment related to stiffness.
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Osteoarthritis (OA) has a very high prevalence among
middle-aged and elderly people and the disease is re-
sponsible for substantial direct and indirect socioeconomic
costs and the treatment options are few and unsatisfactory.
Recently a number of papers have appeared suggesting
pulsed electromagnetic ﬁelds (PEMF) as a technique for
treatment of osteoarthrosis in which technique was applied
oneor a few timesaday for up to amonth1e5. Theassumption
that PEMF promotes beneﬁcial effects was further sub-
stantiated by a recent in vivo study demonstrating a disease-
modifying effect of PEMF in an animal model of OA6.
European League Against Rheumatology has now rated
PEMF treatment for OA as a 1B of evidence and it received
a B rating for strength of recommendation. This was decided
sincenoeffect sizeswere calculable fromprevious data, poor
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2005.57practicality of delivery to the patient population inmost cases,
and due to economic considerations7. Beneﬁcial therapeutic
effects of PEMF have also been documented with increasing
frequency for a variety of bone and cartilage related diseases
since 19738e11. So far, the use of PEMF for treating bone
fractures is, however, the only condition that has received
approval by the Food and Drug Administration in the US.
The mode of action of PEMF is based on creating small
electrical ﬁelds in tissue and thereby promoting biological
effects. When current changes in coils attached to the body
an increasing magnetic ﬁeld appears in the tissue that, in
turn, creates an electrical gradient with a magnitude that
depends on the rate by which the magnetic ﬁeld changes
according to Faraday’s law. The electrical ﬁelds induced in
tissue are of a small magnitude, usually 1e100 mV/cm and
the way by which these ﬁelds activate cell biological
processes is not clariﬁed. We therefore aimed at studying
the efﬁcacy of PEMF treatment in a group of patients
suffering from OA in the knee by using an electrical pulse
pattern frequently applied of 50 Hz and by constructing
placebo devices that made it essentially impossible for the
patients to assess whether or not they were assigned to an
active or a placebo device.5
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STUDY POPULATION
Patients were recruited from the out-patient clinic at the
Department of Rheumatology, Copenhagen University
Hospital in Glostrup from March through to December
2001. Patients older than 45 years with painful knee OA of
the femorotibial compartment fullﬁlling the combined clinical
and radiological criteria of the American College of
Rheumatology were included12. Exclusion criteria were
inﬂammatory joint disease, acromegaly, Charcot’s arthrop-
athy, haemochromatosis, Wilson’s disease, ochronosis,
terminal illnesses/malignancies, pregnancy or lack of
contraception use in women of childbearing age, and use
of pacemaker or any implanted electrical device. Further-
more, patients were excluded if they were unable to
understand/ﬁll out the questionnaires, had received intra-
articular glucocorticoid or hyaluronic acid injection 1 month
prior to study entry, or had hip and/or lumbar spine OA with
referred pain to the study knee. All participants gave written
informed consent. The study was approved by the local
Ethics Committee of Københavns Amt (KA00040g).
DESIGN
This was a 1:1 randomized, controlled, double-blind add-
on study. The duration of the study was 14 weeks and the
patients met for ﬁve visits. Patients were included at
baseline (Visit 1) and met 2 weeks later for randomization
and start of treatment (Visit 2). Treatment was then given for
6 weeks for 2 h daily every 5 of 7 days at the discretion of
the patient. Patients met for a check of compliance after
1e2 weeks of treatment (Visit 3) and met at the end of
treatment (Visit 4). A follow-up and ﬁnal visit was scheduled
6 weeks after the end of treatment (Visit 5). At all visits
a Western Ontario and McMaster Universities (WOMAC)
questionnaire was ﬁlled in and weight, height, and a physical
examination of study knee was done. The physical
examination included measurement of range of movement
(goniometer) and examining for periarticular tendernes
(yes/no) and swelling of the joint (yes/no). Patients were
allowed to continue analgesic medication all through the
study. The radiological features at baseline were examined
according to the Kellgren and Lawrence grading system
of OA13.
TREATMENT WITH PEMF
Two sets of two adjacent coils were placed on the medial
and lateral regions of the study knee, respectively, with the
interspace between the coils being at the level of the joint
line. The coils were placed on an insulating bandage of
3e5 mm thickness that could be tightened by use of Velcro
material. The coils were constructed to ensure a fast rise
time and fast declining phase for current. The use of
adjacent coils creates an ampliﬁed and focused electro-
magnetic ﬁeld. A pulse generator from Biofields Aps,
Copenhagen, Denmark was used that yields G50 V in
50 Hz pulses changing voltage in 3 ms intervals (Fig. 1).
This set up results in a maximal electrical gradient sensed
by charged particles in tissue of 1e100 mV/cm depending
on the distance from the coils14. This value was obtained by
measurements with a differential ampliﬁer in low conducting
media but can also be assessed by integrating the current
density using vector calculus14. A diode ﬂashes in front of
the pulse generator when current is provided for the coils.The patients were instructed to notice that the ﬂashing light
was indicative of current ﬂowing in coils. The device was
constructed in such a way that resistance in the circuitry
(composed of coils) was measured and therefore the light
was ﬂashing only when current was ﬂowing in a fully intact
device for treatment. The current in coils that create PEMF
causes the coils to become slightly warmer than the
surroundings after 30 min (28e35(C). For the group of
patients not receiving active treatment, DC current was
applied to coils yielding a permanent magnetic ﬁeld that
does not evoke changing electrical potentials in tissue. We
calculated the effect delivered to the active coils (PEMF)
and delivered the same effect (in DC current) to the placebo
coils. Thereby the coils in the active and placebo groups
had the identical increase in temperature. The patients were
instructed that coils from both groups would exhibit a slight
increase in temperature. The diode on the pulse generators
ﬂashes in a similar fashion in both cases when current is
ﬂowing. Thus, by use of this set up, patients in the two
groups could detect the exact same heat from the coils and
were unable to determine to which group they were
assigned. There was no transfer of heat from coils to the
knee due to the insulating material.
OUTCOME MEASURES
Symptoms of knee OA were assessed by the WOMAC
OA index15, a questionnaire addressing severity of joint
pain (ﬁve questions), stiffness (two questions), and limita-
tion of physical function (17 questions). The version using
verbal rating scales of the WOMAC index was used e i.e.,
with the patient assessing each question by none (1),
mild (2), moderate (3), severe (4), and extreme (5). A
higher WOMAC score thereby represents worse symptoms
severity.
WOMAC subscore of joint pain was the primary outcome
measure (0e25). WOMAC subscores of stiffness (0e10),
activities of daily living (ADL) (0e85), and scintigraphic
results were secondary outcome measures.
Fig. 1. Changes in current and voltage in coils used for PEMF
treatment. The pulse is initiated by applying C50 V to the coil and
after 3 ms e 50 V whereby coils are exposed to a 100 mV potential
change. After 6 ms the voltage is zero. Pulses occur with 50 Hz
frequency. Changes in electromotoric force (EMF) on charged
particles in tissue is proportional to: EMFZ dB/dt, where B is the
magnetic ﬁeld proportional to the current (A) and t is the time. It was
calculated and measured that the electrical ﬁeld 1 cm from the coil
amounted to approximately 10 mV/cm.
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processes in particular in younger patients we designed the
trial in such a way that a separate estimate should be
performed on patients !65 years after all data were
accumulated.
STATISTICAL METHODS
Specially designed case report forms were used to collect
data. Blinding was maintained until the ﬁnal database was
cleaned and locked. Baseline values were calculated as the
mean value for the ﬁrst two visits. An analysis based on
intention to treat with last observation carried forward as
well as an analysis of patients who ﬁnished per protocol
was done. Parametric or non-parametric statistical tests
were used depending on whether the data followed
a Gaussian or non-Gaussian distribution. Comparisons
within groups were done by Student’s paired t test and
comparisons between groups were done by a two-way
repeated measures ANOVA (one factor repetition). A
P-level of%0.05 was considered as revealing signiﬁcance.
Based on an SD of 3.5, we calculated that a sample size of
90 patients would give a power of 90% in detecting a more
than 2.5 (10%) difference in the WOMAC subscore of joint
pain at the 5% level of signiﬁcance. Data are given as mean
(SD) unless indicated otherwise.
BONE SCINTIGRAPHY
Late phase bone uptake was recorded 180 min after the
injection of 500 MBq 99mTc-MDP. Three 6 min frames were
recorded in anterior, posterior and lateral views using
a high-resolution collimator on a dual-head gamma camera
(Forte, ADAC Laboratories, Milpitas, USA). Matrix size was
256! 256. Images of the relevant study knee were
displayed on a high-resolution computer screen using
a monochrome color scale and a standard display software
package (Pegasys Ultra, ADAC Laboratories). Quantiﬁca-
tion was performed blindly by placing pre-deﬁned rectan-
gular regions of interest (ROI) over the knee joint (covering
a ﬁeld from 1.4 cm proximal to 1.4 cm distal to the joint line)
(Knee Joint), the whole knee region (Whole Knee), and
a reference ROI placed over the femoral bone 19 cm
proximal to the knee16. Knee to reference ROI ratios
(Ratios) were calculated without background subtraction.
Results
CHARACTERISTICS AT BASELINE
One hundred and ﬁfty-ﬁve patients were screened and 90
fulﬁlled the study criteria and were randomized to study
treatment. Eighty-three patients completed the study
without protocol violations after ﬁnishing the protocol they
were included in the analysis and the results are given
below. An analysis based on the intention to treat principle
with last observation carried forward gave similar results as
all non-completers left the study before Visit 3. Patients
were randomized into the active PEMF group (45 patients)
and into the control group (45 patients). Before ending
treatment three withdrew from the PEMF group and four
from the control group. Thus, 42 completed in the PEMF
group and 41 in the control group. The patient character-
istics from the two groups are shown in Table I. There were
no signiﬁcant differences between the groups with respectto age, body mass index (BMI), gender, disease duration,
and Kellgren and Lawrence score.
At baseline 23 of 42 patients in the PEMF group used
analgesic medication (55%) e eight patients used non-
steroidal anti-inﬂammatory drug (NSAIDs), 10 patients used
analgesics (paracetamol or weak opioids), and ﬁve patients
used both NSAIDs and analgesics. At baseline 25 of 41
patients in the placebo group used analgesic medication
(61%) e 13 patients used NSAIDs, seven patients used
analgesics (paracetamol or weak opioids), and ﬁve patients
used both NSAIDs and analgesics. At the end of treatment
in the PEMF group two patients had increased and one
patient had decreased consumption of analgesic medica-
tion whereas in the placebo group one patient had
increased and three patients had decreased consumption
of analgesic medication.
ADL, PAIN AND STIFFNESS
WOMAC subscores of ADL are given in Table II(a). In the
PEMF group there was a signiﬁcant fall in the WOMAC
subscore of ADL during treatment, at the end of treatment,
and at follow-up. In the placebo group there was a signif-
icant fall at the end of treatment and at follow-up, but not
during treatment. At the end of treatment there was a fall in
Table I
Baseline demographics and clinical characteristics in two groups of
patients with knee OA randomized to receive PEMF (nZ 42) or
placebo (nZ 41) in a therapeutic study
PEMF Placebo
Age (years) 60.4 (8.7) 59.6 (8.6)
BMI (kg/m2) 27.0 (4.0) 27.5 (5.7)
Females (n) 20 25
Males (n) 23 16
Disease duration (years) 7.5 (5.2) 7.9 (7.7)
Kellgren and Lawrence score (0e4) 2.5 (1.2) 2.8 (1.1)
Analgesic medication (n) 28 29
Table II
WOMAC data on ADL, pain and stiffness
Week PEMF Placebo Two-way
ANOVA
Mean SE P value Mean SE P value
(a) WOMAC data on ADL from patients
treated with or without PEMF
0 43.83 1.93 46.49 2.21
2 40.46 2.05 0.010* 44.54 2.25 0.29 0.524
6 37.63 1.73 0.00004* 42.44 2.38 0.05* 0.619
12 37.89 2.14 0.00007* 41.37 2.27 0.02*
(b) WOMAC data on pain from patients treated
with or without PEMF
0 13.15 0.57 14.49 0.54
2 11.93 0.53 0.12 13.20 0.54 0.12 NS
6 11.68 0.48 0.05* 12.36 0.66 0.14 NS
12 11.40 0.57 0.03* 12.24 0.63 0.01*
(c) WOMAC data on stiffness from patients treated
with and without PEMF
0 5.74 0.29 5.85 0.28
2 5.10 0.27 0.11 5.49 0.32 0.40 0.620
6 4.90 0.25 0.03* 5.32 0.32 0.21 0.567
12 4.81 0.32 0.04* 5.15 0.30 0.09
NS, not signiﬁcant; *P% 0.05.
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in the placebo group. Between group analysis using a two-
way ANOVA with replication revealed no signiﬁcant
difference between the PEMF-treated group and the
placebo group. WOMAC subscores of pain are given in
Table II(b). In both groups there was at the follow-up
a signiﬁcant fall in the WOMAC subscore of 15%. There
were no signiﬁcant differences between the two groups at
any time point using the two-way ANOVA.
Regarding stiffness there was a signiﬁcant fall in the
PEMF-treated group at the end of treatment and at the
follow-up which was not observed for the placebo group. At
the follow-up there was a decrease of 16% in the PEMF-
treated group and 12% in the placebo group. The two-way
ANOVA revealed no signiﬁcant difference between groups
at any point.
ADL, PAIN AND STIFFNESS FOR PATIENTS !65 YEARS
Since effects of PEMF is expected to initiate growth and
differentiation of living tissue we anticipated that PEMF
might have more effect in patients with a larger growth
potential for osteoblasts, chondrocytes, and possibly able to
evoke an enhanced blood ﬂow in a relatively young
population. In the design we therefore decided to evaluate
patients!65 years. We analyzed the relation between age
and changes in ADL WOMAC score as measured by
difference between the score before treatment and the
score measured after 6 weeks of treatment (end of
treatment). When plotting the differences in ADL WOMAC
scores vs age we found that there was a signiﬁcant
correlation between increase in age and decrease in
reported improvement (PZ 0.05) of the PEMF-treated
group as shown in Fig. 2. This correlation was not observed
for the control group (PZ 0.57). Kellgren scores for patients
!65 years were 2.50G 1.00 (SD) for the PEMF-treated
group and 2.57G 1.14 (SD) for the placebo group. Average
ages were 56.7 years and 55.3 years, respectively. We
analyzed the effects of treatment on ADL, pain and stiffness
for the treated and placebo groups !65 years. There were
31 patients in each group (PEMF-treated and placebo). The
data analysis revealed that there were signiﬁcant improve-
ments for ADL, pain and stiffness for the PEMF-treated
groups and that the effect was only observed in the placebo
group at the follow-up for ADL [Table III(aec)]. With regard
to stiffness a highly signiﬁcant difference was seen between
baseline and 2, 6, and 14 weeks for the PEMF-treatedgroup. There was a 19% improvement in the PEMF-treated
group at the follow-up which only amounted to 8% for the
placebo group. Between group analysis using a two-way
ANOVA on stiffness revealed a signiﬁcant improvement
after 2 weeks (PZ 0.032) and a smaller signiﬁcance level
(PZ 0.072) was observed after 6 weeks. Thus, PEMF
treatment reduces stiffness of joints for patients!65 years
when evaluated using in between group analysis.
PHYSICAL EXAMINATION
The results of the physical examinations were compara-
ble in the two study groups at baseline. There were no
changes in the results of the physical examinations, in
weight or in height within or between the groups during
study treatment or follow-up (data not shown).
ADVERSE EFFECTS
There were no serious adverse effects and there were no
drop outs from the study for reasons related to the
Table III
WOMAC data on ADL, pain and stiffness
Week PEMF Placebo Two-way
ANOVA
Mean SE P value Mean SE P value
(a) WOMAC data on ADL from patients !65 years
treated with or without PEMF
0 43.26 2.35 47.90 2.35
2 39.64 2.42 0.0242* 45.13 2.42 0.18 0.742
6 35.58 1.91 0.0001* 42.87 1.91 0.02* 0.581
12 37.06 2.37 0.0034* 41.23 2.37 0.002*
(b) WOMAC data on pain from patients !65 years
treated with or without PEMF
0 13.34 0.73 14.67 0.70
2 11.80 0.65 0.014* 13.68 0.80 0.003* 0.476
6 11.43 0.59 0.008* 12.81 0.83 0.0005* 0.715
12 11.37 0.69 0.007* 12.80 0.77 0.0006*
(c) WOMAC data on stiffness from patients !65 years
treated with or without PEMF
0 5.65 0.37 5.81 0.36
2 4.81 0.33 0.09 5.68 0.40 0.81 0.032*
6 4.65 0.32 0.04* 5.52 0.40 0.59 0.071
12 4.55 0.37 0.04* 5.35 0.38 0.39
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Fig. 2. Changes in ADL WOMAC score as a function of age for the PEMF-treated (A) and placebo (B) group. Ordinates show differences
between initial scores before treatment and scores measured after 6 weeks (end of treatment). Linear regression analysis of data reveals
a slope of 30G 0.15 (PZ 0.05) for the PEMF-treated group and 0.09G 0.19 (PZ 0.57) for the placebo group.
579Osteoarthritis and Cartilage Vol. 13, No. 7treatment. In the PEMF group four patients reported
a grumbling or throbbing sensation, six patients reported
a warming sensation, and two patients reported an
aggravation of the osteoarthritic pain in the study knee. In
the control group the corresponding ﬁgures were four, one,
and one, respectively. In all cases the adverse effects took
place within the ﬁrst 2 weeks of treatment and were mild
and transient.
BONE SCINTIGRAPHY
The results of the bone scintigraphic examinations are
given in Table IV. To distinguish activity in the patello-
femoral compartment from that in the tibio-femoral com-
partment, ratios obtained with the lateral view are given
separately (Whole Knee-lat, Knee Joint-lat). The ratios in
the two study groups were comparable at the start of
treatment. There were no changes within or between the
groups that could be attributed to the study treatment.
Discussion
The aim of the study was to evaluate the efﬁcacy and
applicability of the PEMF technology for improving the
conditions for patients suffering from OA. We chose to
evaluate for global assessment, ADL, stiffness and pain.
The important design in this study was ﬁrstly, that patients
were treated for 6 weeks and the ﬁnal evaluation was
conducted after 6 more weeks to evaluate if improvements
would sustain over time. The results in this study showed
that there was a rapid improvement in ADL, pain and
stiffness for the PEMF-treated group e an effect not as
pronounced in the placebo group. Between group analysis
using a two-way repeated measures ANOVA did not show
a signiﬁcant difference between the PEMF-treated and
placebo groups. However, when the patient group was
reduced to !65 years of age there was a signiﬁcant
improvement at early time points for stiffness but not for
ADL and pain.
There were no obvious ﬂaws in the conduct of our study.
At baseline the PEMF-treated and the control patients did
not differ in any signiﬁcant respect. As assessed from the
diaries, the compliance was high, and we have no reasons
to believe that the patients did not adhere to treatment. We
used the WOMAC questionnaire, which is a validated,
Table IV
Bone scintigraphic results for study knee at baseline and at the end
of treatment (6 weeks) with PEMF (nZ 18) or placebo (nZ 18) in
patients with OA of the knee. The values are given as mean (SD).
No significant differences within or between groups. For explana-
tion of Site and Ratios, see Methods and Results sections
Site Treatment Ratio
Baseline End of treatment
Whole Knee Placebo 3.0 (1.0) 2.9 (1.3)
PEMF 2.8 (1.8) 2.7 (1.5)
Knee Joint Placebo 2.0 (0.5) 2.0 (0.8)
PEMF 1.8 (0.9) 1.8 (0.7)
Whole Knee-lat Placebo 3.2 (1.2) 3.1 (1.1)
PEMF 3.1 (1.9) 3.0 (1.7)
Knee Joint-lat Placebo 2.0 (0.6) 1.9 (0.5)
PEMF 1.7 (0.8) 1.8 (0.8)disease speciﬁc, and sensitive measurement of symptoms
related to knee OA12. The number of patients enrolled in the
study was sufﬁcient to ensure a high probability of detecting
a clinical relevant improvement in the PEMF-treated
patients. An add-on design was chosen, and therefore
patients continued their individual analgesic medication
(paracetamol, NSAID, or weak opioids). Only a few patients
changed their analgesic medication in the study period.
More patients in the placebo than in the PEMF group
decreased the analgesic medication, and less patients in
the placebo than in the PEMF group increased the
analgesic medication. It is, therefore, unlikely that a possible
analgesic effect of PEMF was affected by a counter
regulatory decrease in the analgesic medication. Further-
more, coils for the placebo device were constructed in such
a way that they were indistinguishable from the active coils
for the PEMF-treated group by releasing the same amount
of heat. Thus, patients were unable to determine to which
group they were assigned.
We observed a placebo effect in most outcomes of
8e14% which is expected in this type of trials, in particular
since the control device, like the active device, generated
some heat. Thus, patients in both groups could to the same
extent get the impression that they were being treated
although information about these factors was given at the
onset of the trial.
Our ﬁndings are in some respects in accordance with
previous observations1e3 describing improved functional
performance of PEMF-treated patients both in relation to
OA of the knee as well as OA of cervical spine. Our data
differ from the data by Zizic et al.4, in our ﬁnding, that pain
score is not signiﬁcantly improved when data are analyzed
between groups. Our improvement on mobility is also
somewhat smaller than that reported by Trock et al.2
Recently, Pipetone and Scott5 reported a signiﬁcant im-
provement within groups treated with PEMF e a ﬁnding that
was not observed in the placebo group. They, however, did
not perform between group analysis. We could by using
between group analysis demonstrate improvement with
regard to stiffness which was not demonstrated in the study
by Pipitone and Scott5. Thus, it appears that in group
analysis of PEMF treatments consistently gives the result
that there is an improvement on ADL and mobility which is
slightly better than that seen for the placebo groups when
they are evaluated based on their signiﬁcance levels.
Therefore, in between group analysis is essential in order to
demonstrate whether or not improvements have occurred
based on treatment. Although we found a much better
signiﬁcance level on PEMF treatments for ADL and
stiffness compared to placebo for all patients we could not
demonstrate improvements based on treatment from
between group analysis. However, when evaluating pa-
tients !65 years of age we did ﬁnd a signiﬁcant improve-
ment on the stiffness of the knee revealing a possible
improvement in mobility of the joint treated.
Considerable amount of experimental data have now
emerged demonstrating an anabolic effect of PEMF on
osteoblasts and chondrocytes10,17e19. A putative positive
effect of PEMF on bone and cartilage metabolism in knee
OA may not necessarily improve symptoms within the short
duration of the present study. To detect subtle short-term
changes in remodeling of the subchondral bone in the study
knee, we therefore performed bone scintigraphies using
a semiquantitative measurement. Unfortunately, we were
unable to demonstrate an effect of PEMF on bone
metabolism. No reliable and sensitive method exists to
detect and monitor subtle changes in cartilage metabolism
580 G. Thamsborg et al.: Treatment of knee OA with PEMFin a similar way. Therefore, we do not know whether PEMF
affected cartilage metabolism.
It is relevant to compare the effects of PEMF treatment
with the improvement in stiffness due to treatment with
ibuprofen evaluated on a similar WOMAC scale12. These
data show that with regard to stiffness there is a strong
effect after 2 and 4 weeks treatment with ibuprofen (2.4 g/
day) amounting to 24% and 40% improvement. For ADL the
effects were 25% and 33%. This is a stronger effect than
that seen in this study, but it should be noted that the
improvement in stiffness of 19% on the WOMAC scale seen
in our study occurred on patients (!65 years) who were
already under medications.
Recently, a number of papers have appeared from
studies on cell cultures as well as animal studies that
attempt to explain how PEMF activates cells and induce
proliferation and differentiation. It has been suggested that
cytoplasmic tyrosine kinases of the Src family like Lyn
becomes activated14,20e22. On endothelial cells as well as
chondrocyte cell cultures (ATDC5) we have recently found
that our pulsed ﬁelds activate the cytoplasmic Src kinase by
phosphorylating the activation site and dephosphorylating
the inhibitory site (data not shown). Recently it was
shown6,23 that low frequency PEMF regulates chondrocyte
differentiation and the expression of matrix proteins in
immature male rats and that in rabbits PEMF stimulates
cartilage differentiation and endochondrial ossiﬁcation
which was coincident with an increase in transforming
growth factor (TGFa) expression. Within the last 10 years
a considerable amount of literature describing PEMF
activated biological processes have been focusing on the
fact that existing biochemical processes becomes facilitated
by the pulsed ﬁelds e especially in relation to cell
proliferation of chondrocytes17,18. In relation to enhanced
growth and differentiation of chondrocytes and function of
joints the two growth factors TGFa and insulin-like growth
factor (IGF) are essential activators of chondrocytes. It is
therefore interesting that expression of TGFa proteins are
enhanced following PEMF treatment20 and that the receptor
type for TGFa is facilitated presumably through activation of
cytoplasmic tyrosine kinases. Thus, PEMF activation as
used in this study can activate cellular processes although
the mechanism by which it occurs is far from clariﬁed.
Improvement on stiffness could be envisioned as being due
to (1) an enhanced blood circulation in the periarticular
compartment, (2) improved growth of chondrocytes or (3)
positive effects on cartilage differentiation. A possible
explanation for the improved mobility on the treated joint
on a short basis of 2 weeks could be an enhanced blood
ﬂow. Support for this idea could be found in the observation
that PEMF activates synthesis of nitric oxide (NO)19 and
synthesis of NO in endothelial cells could be involved in
enhancing blood ﬂow. Furthermore, it was recently shown
that PEMF increases in vivo and in vitro angiogenesis
through endothelial release of ﬁbroblast growth factor-2, an
important angiogenic factor24. Thus, there are data in-
dicating that improved blood circulation in the periarticular
compartment could occur following treatment. Recent data
from several laboratories have suggested that PEMF
activates cellular signaling processes rapidly within
5e10 min14,20e22 and signaling is largely blunted after
30 min. Thus, future studies could beneﬁt from applying
a shorter duration of PEMF-stimulation, that is, less than 1 h
but several times a day.
In conclusion, there was for all patients with knee OA
a tendency towards an initial transient improvement and in
group analysis revealed a high signiﬁcance level whencompared to baseline. Between group analysis of all
patients did however not show a signiﬁcant effect of
treatment. When the group was reduced to those !65
years there was still a tendency towards a rapid improve-
ment on ADL, pain and stiffness on the WOMAC scale and
there was furthermore a signiﬁcant effect on stiffness using
between group analysis. Thus, improved mobility of joints
exposed to PEMF is a possible outcome of the treatment. In
order to fully characterize a possible useful clinical effect of
PEMF treatment further analysis should be performed on
patients of different age groups and using different
durations of treatment.
Acknowledgements
We appreciate economical support from IMK Almene Fond
and from Københavns Amts Erhvervskontor.
References
1. Trock DH, Bollet AJ, Dyer RH Jr, Fielding LP, Miner
WK, Markoll R. A double-blind trial of the clinical
effects of pulsed electromagnetic ﬁelds in osteoarthri-
tis. J Rheumatol 1993;20:456e60.
2. Trock DH, Bollet AJ, Markoll R. The effect of pulsed
electromagnetic ﬁelds in the treatment of osteoarthritis
of the knee and cervical spine. Report of randomized,
double-blind, placebo-controlled trials. J Rheumatol
1994;21:1903e11.
3. Trock DH. Electromagnetic ﬁelds and magnets. In-
vestigational treatment for musculoskeletal disorders.
Rheum Dis Clin North Am 2000;26:51e62.
4. Zizic TM, Hoffman KC, Holt PA, Hungerford DS, O’Dell
JR, Jacobs MA, et al. The treatment of osteoarthritis of
the knee with pulsed electrical stimulation. J Rheu-
matol 1995;9:1757e61.
5. Pipitone N, Scott DL. Magnetic pulse treatment for knee
osteoarthritis: A randomised, double-blind, placebo-
controlled study. Curr Med Res Opin 2001;17:190e6.
6. Ciombor DM, Aaron RK, Wang S, Simon B. Modiﬁca-
tion of osteoarthritis by pulsed electromagnetic ﬁeld e
a morphological study. Osteoarthritis Cartilage 2003;
11(6):455e62.
7. Jordan KM, Arden NK, Doherty M, Bannwarth B,
Bijlsma JW, Dieppe P, et al. EULAR recommendations
2003: an evidence based approach to the manage-
ment of knee osteoarthritis: Report of a task force of
the standing committee for international clinical stud-
ies including therapeutic trials. Ann Rheum Dis 2003;
62:1145e55.
8. Basset CA, Mitchell SN, Gaston SR. Treatment of
ununited tibial diaphyseal fractures with pulsing
electromagnetic ﬁelds. J Bone Joint Surg 1981;63:
511e23.
9. Bassett CA, Pilla AA, Pawluk RJ. A non-operative
salvage of surgically-resistant pseudarthroses and
non-unions by pulsing electromagnetic ﬁelds. Clin
Orthop 1977;124:128e43.
10. Aaron RK, Boyan BD, Ciombor DM, Schwartz Z, Simon
BJ. Stimulation of growth factor synthesis by electric
and electromagnetic ﬁelds. Clin Orthop 2004;419:
30e7.
11. Bodamyali T, Bhatt B, Hughes FJ, Winrow VR,
Kanczler JM, Simon B, et al. Pulsed electromagnetic
ﬁelds simultaneously induce osteogenesis and upre-
gulate transcription of bone morphogenetic proteins 2
581Osteoarthritis and Cartilage Vol. 13, No. 7and 4 in rat osteoblasts in vitro. Biochem Biophys Res
Commun 1998;250:458e61.
12. Bellamy N, Buchanan WW, Goldsmith CH, Campell J,
Stitt LW. Validation study of WOMAC: a health status
instrument for measuring clinically important patient
relevant outcomes to antirheumatic drug therapy in
patients with osteoarthritis of the hip or knee.
J Rheumatol 1988;15:1833e40.
13. Kellgren JH, Lawrence JS. Radiological assessment of
osteoarthritis. Ann Rheum Dis 1957;16:494e501.
14. Rahbek UL, Tritsaris K, Dissing S. Interactions of low
frequency, pulsed electromagnetic ﬁelds with living
tissue: biochemical responses and clinical results.
Oral Biosci Med 2005;2(1).
15. Davies GM, Watson DJ, Bellamy N. Comparison of the
responsiveness and relative effect size of the Western
Ontario and McMaster Universities Osteoarthritis In-
dex and the short-form Medical Outcomes Study
Survey in a randomized, clinical trial of osteoarthritis
patients. Arthritis Care Res 1999;12(3):172e9.
16. McCrae F, Shouls J, Dieppe P, Watt I. Scintigraphic
assessment of osteoarthritis of the knee joint. Ann
Rheum Dis 1992;51(8):938e42.
17. DeMattei M, Caruso A, Pezzetti F, Pellati A, Stabellini G,
Sollazzo V, et al. Effects of pulsed electromagnetic
ﬁelds on human articular chondrocyte proliferation.
Connect Tissue Res 2001;42(4):269e79.
18. Pezzetti F, De Mattei M, Caruso A, Cadossi R,
Zucchini P, Carinci F, et al. Effects of pulsedelectromagnetic ﬁelds on human chondrocytes: an in
vitro study. Calcif Tissue Int 1999;65(5):396e401.
19. Diniz P, Soejima K, Ito G. Nitric oxide mediates the
effects of pulsed electromagnetic ﬁeld stimulation on
the osteoblast proliferation and differentiation. Nitric
Oxide 2002;7(1):18e23.
20. Uckun FM,Kurosaki T, Jin J, JunX,MorganA, TakataM,
et al. Exposure of B-lineage lymphoid cells to low
energy electromagnetic ﬁelds stimulates Lyn kinase.
J Biol Chem 1995;270:27666e70.
21. Kristupaitis D, Dibirdik I, Vassilev A, Mahajan S,
Kurosaki T, Chu A, et al. Electromagnetic ﬁeld-
induced stimulation of Bruton’s tyrosine kinase. J Biol
Chem 1998;273:12397e401.
22. Dibirdik I, Kristupaitis D, Kurosaki T, Tuel-Ahlgren L,
Chu A, Pond D, et al. Stimulation of Src family protein-
tyrosine kinases as a proximal and mandatory step for
SYK kinase-dependent phospholipase Cg2 activation
in lymphoma B cells exposed to low energy electro-
magnetic ﬁelds. J Biol Chem 1998;273:4035e9.
23. Ciombor DMcK, Lester G, Aaron RK, Neame P,
Caterson B. Low frequency EMF regulates chondro-
cyte differentiation and expression of matrix proteins.
J Orthop Res 2002;20(1):40e50.
24. Tepper OM, Callaghan MJ, Chang EI, Galiano RD,
Bhatt KA, Baharestani S, et al. Electromagnetic ﬁelds
increase in vitro and in vivo angiogenesis through
endothelial release of FGF-2. FASEB J 2004;18(11):
1231e3.
